rtmark
LearnBonds.com

CVS Health Stock Remains Strong Due to Increased Interest in Private Health Insurance

CVS pharmacy store

Despite an almost 20% decline in stock since the beginning of this year, CVS Health (NYSE: CVS) stock retains a strong price of $60 per share and boats a significant upside. CVS Health’s stock is 20% lower than it was at the beginning of 2019 and around 11% lower than it was at the start of 2018.

Part of the reason for the decline of the stock price over the last two years was due to the company’s massive $69 billion acquisition of Aetna, resulting in $42 billion incremental debt between 2017 and 2019. The company experienced revenue growth of 39%, led by the Aetna acquisition from 2017 to 2019. At the same time, net income margins dropped 27.9% from 3.6% to 2.6% over the same period. Higher employee costs, financing costs, and goodwill impairments were all contributing factors. Given the Aetna acquisition, total share count also increased by 27%. All these factors led to a 21% decline in EPS between 2017 and 2019.

CVS Health Stock Remains...

With the latest developments in the nationwide lockdown as a result of the looming coronavirus pandemic, analysts expect to see growth in CVS Health’s P/E multiple and the company’s EPS  in the coming years. The company in February guided for GAAP EPS to be in the range of $5.47 and $5.60 in 2020, compared to $5.08 in 2019.

CVS Health’s near term performance is likely to feel the effect of the global spread of the coronavirus, particularly in its insurance business. The company is waiving cost-sharing for certain Aetna members, who are hospitalized for coronavirus treatment. As such, CVS Health’s stock has lost 16% of its value between January 31st and April 8 (vs. about an 18% decline in the S&P 500).

Now, that the US has become the new epicentre of the outbreak, there is an increase in the demand for private health insurance. Total uninsured non-elderly population was nearly 30 million in 2018. With the current outbreak, people are looking for alternatives for their health insurance for protection, with the uninsured rate expected to take a dip in the near term. As CVS’ retail pharmacy stores remain open across the globe while most of the other stores remain in the lockdown, the near term impact from the current crisis will likely produce some potential upside returns.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
Users should remember that all trading carries risks and users should only invest in regulated firms. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Galina Mikova

Galina is a Hubspot-certified Technical Writer with over 10 years of experience in working with Fortune 500, private investment, banking, FOREX and niche tech companies as well as crypto and blockchain startups. She has a solid background in FinTech and blockchain technology.